AMDIS/HIMSS: No doc 'plays with a full deck'

NEW ORLEANS—“We’re all playing with half a deck,” said Lawrence L. Weed, MD, the father of the problem-oriented medical record, speaking during the AMDIS Physicians’ IT Symposium at the Healthcare Information and Management Systems Society (HIMSS) annual conference.

Weed, professor of medicine emeritus at the College of Medicine, University of Vermont in Burlington, Vt., quoted everyone from Francis Bacon to Oscar Wilde during his talk. “No two doctors play with the same part of the deck and no one plays with a full deck,” he said about health information.

Also, Weed expressed surprise that the Institute of Medicine’s estimate that 500,000 people a year die due to medical errors, hasn’t caused more outrage. In an age when a plane crash makes the evening news for several days, Weed said the medical industry should be more concerned about its preventable errors. “We’re in the dark ages when it comes to moving information.”

One of the problems, he said, is that “medicine is a $2.5 trillion industry with no accounting system.”

The transportation system, meanwhile, works because the knowledge is in the system not in people’s heads. “Always teach a core of behavior, not a core of knowledge, as knowledge is forgotten,” he said.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.